Abstract
Dengue fever is caused by infection with one of four dengue virus (DENV) serotypes (DENV-1-4), necessitating tetravalent dengue vaccines that can induce protection against all four DENV. Takeda's live attenuated tetravalent dengue vaccine candidate (TDV) comprises an attenuated DENV-2 strain plus chimeric viruses containing the prM and E genes of DENV-1, -3 and -4 cloned into the attenuated DENV-2 'backbone'. In Phase 1 and 2 studies, TDV was well tolerated by children and adults aged 1.5-45 years, irrespective of prior dengue exposure; mild injection-site symptoms were the most common adverse events. TDV induced neutralizing antibody responses and seroconversion to all four DENV as well as cross-reactive T cell-mediated responses that may be necessary for broad protection against dengue fever.
Keywords:
Dengue; TDV development; clinical immunology; dengue-endemic; dengue-seropositive participants; live attenuated tetravalent vaccine; safety.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Neutralizing / blood
-
Antibodies, Viral / blood
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Dengue / immunology
-
Dengue / prevention & control*
-
Dengue Vaccines / adverse effects
-
Dengue Vaccines / genetics
-
Dengue Vaccines / immunology*
-
Dengue Virus / genetics
-
Dengue Virus / immunology*
-
Drug-Related Side Effects and Adverse Reactions / epidemiology
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Humans
-
Serogroup
-
T-Lymphocytes / immunology
-
Treatment Outcome
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / genetics
-
Vaccines, Attenuated / immunology
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Dengue Vaccines
-
Vaccines, Attenuated
-
Vaccines, Synthetic
-
Viral Envelope Proteins
-
prM protein, Flavivirus